<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>10014938</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">36918579</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">10014938</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">339</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1038/s41537-023-00339-y</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Sample characteristics at baseline and follow-up.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Sample characteristics at baseline and follow-up.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Baseline</th><th>Control subjects<sup>a</sup><italic>N</italic> = 60</th><th>FEP patients<sup>a</sup><italic>N</italic> = 76</th><th>Group Difference<sup>b</sup></th></tr></thead><tbody><tr><td>Male</td><td>38 (63.3)</td><td>51 (67.10)</td><td><italic>p</italic> = 0.686</td></tr><tr><td>Age</td><td>23.97 (19.10–43.87, 6.83)</td><td>23.98 (18.26–39.06, 6.55)</td><td><italic>p</italic> = 0.420</td></tr><tr><td>Years of education</td><td>15.00 (11.00–22.00, 3.50)</td><td>12.50 (9.00–22.00, 3.88)</td><td><italic>p</italic> = 0.004</td></tr><tr><td>BPRS 10</td><td>1 (1–1, 0.00)</td><td>2 (1–6, 4.00) (<italic>N</italic> = 75)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td>BPRS 11</td><td>1 (1–2, 0.00)</td><td>4 (1–7, 5.00) (<italic>N</italic> = 75)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td>BPRS 12</td><td>1 (1–1, 0.00)</td><td>1 (1–6, 1.00) (<italic>N</italic> = 75)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td>BPRS 15</td><td>1 (1–2, 0.00)</td><td>1 (1–5, 0.00) (<italic>N</italic> = 75)</td><td><bold><italic>p</italic></bold> = <bold>0.003</bold></td></tr><tr><td>BPRS 16</td><td>1 (1–3, 0.00)</td><td>1 (1–5, 2.00) (<italic>N</italic> = 75)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td>SANS 1</td><td>0.00 (0.00–1.00, 0.00)</td><td>0.00 (0.00–3.00, 1.00) (<italic>N</italic> = 75)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td>SANS 2</td><td>0.00 (0.00–1.00, 0.00)</td><td>2.00 (0.00–5.00, 3.00) (<italic>N</italic> = 75)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td>SANS 3</td><td>0.00 (0.00–2.00, 0.00)</td><td>3.00 (0.00–5.00, 2.00) (<italic>N</italic> = 75)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td>Antipsychotic dose</td><td>0.00 (0.00–0.00, 0.00)</td><td>300.00 (0.00–1320.00, 300.00)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td>GAF</td><td>85.00 (55–95, 14.25)</td><td>37.50 (15–75, 8.00)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td rowspan="10">DSM-IV diagnosis</td><td>296.25/296.26/296.32/296.36 Major depressive disorder (<italic>n</italic> = 10)</td><td>292.12 Drug induced psychotic episode, cannabis (<italic>N</italic> = 1)</td><td rowspan="10"/></tr><tr><td>300.21 Panic disorder with agoraphobia (<italic>n</italic> = 1)</td><td>295.3 Paranoid schizophrenia (<italic>n</italic> = 12)</td></tr><tr><td>300.23 Social phobia (<italic>n</italic> = 1)</td><td>295.4 Schizophreniform disorder (<italic>n</italic> = 18)</td></tr><tr><td>300.3 Obsessive-compulsive disorder (<italic>n</italic> = 1)</td><td>295.7 Schizoaffective disorder (<italic>n</italic> = 1)</td></tr><tr><td>305 Alcohol abuse (<italic>n</italic> = 1)</td><td>295.9 Schizophrenia undefined (<italic>n</italic> = 15)</td></tr><tr><td>307.1 Anorexia Nervosa (<italic>n</italic> = 1)</td><td>296.04/296.44 Bipolar type 1 disorder (<italic>n</italic> = 7)</td></tr><tr><td rowspan="4">311 Depressive disorder NOS (<italic>n</italic> = 1)</td><td>296.24/296.34 Major depressive affective disorder with psychotic features (<italic>n</italic> = 4)</td></tr><tr><td>298.8 Brief psychotic disorder with psychotic features (<italic>n</italic> = 2)</td></tr><tr><td>298.9 Unspecified psychosis (<italic>n</italic> = 15)</td></tr><tr><td>300 OCD (<italic>n</italic> = 1)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th>Follow-up</th><th>Control subjects<sup>a</sup><italic>N</italic> = 43</th><th>FEP patients<sup>a</sup><italic>N</italic> = 48</th><th>Group Difference<sup>b</sup></th></tr></thead><tbody><tr><td>Male</td><td>32 (74.40)</td><td>29 (60.40)</td><td><italic>p</italic> = 0.179</td></tr><tr><td>Age</td><td>25.24 (21.07–41.50, 6.63)</td><td>25.16 (19.41–36.93, 5.70)</td><td><italic>p</italic> = 0.382</td></tr><tr><td>BPRS 10</td><td>1 (1–2, 0.00)</td><td>2 (1–6, 0.00)</td><td><italic>p</italic> = 0.070</td></tr><tr><td>BPRS 11</td><td>1 (1–2, 0.00)</td><td>4 (1–7, 1.00)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td>BPRS 12</td><td>1 (1–1, 0.00)</td><td>1 (1–4, 0.00)</td><td><italic>p</italic> = 0.057</td></tr><tr><td>BPRS 15</td><td>1 (1–2, 0.00)</td><td>1 (1–4, 0.00)</td><td><italic>p</italic> = 0.214</td></tr><tr><td>BPRS 16</td><td>1 (1–2, 0.00)</td><td>1 (1–4, 1.00)</td><td><bold><italic>p</italic></bold> = <bold>0.002</bold></td></tr><tr><td>SANS 1</td><td>0.00 (0.00–0.00, 0.00)</td><td>0.00 (0.00–3.00, 0.00)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.006</bold></td></tr><tr><td>SANS 2</td><td>0.00 (0.00–2.00, 0.00)</td><td>1.00 (0.00–4.00, 2.00)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td>SANS 3</td><td>0.00 (0.00–2.00, 0.00)</td><td>3.00 (0.00–4.00, 3.00)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td>Antipsychotic dose</td><td>0.00 (0.00–60.00, 0.00)</td><td>190.00 (0.00–1050.00, 273.75)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr><tr><td>GAF</td><td>85.00 (40–96, 11.25)</td><td>50.00 (30–90, 28.00)</td><td><bold><italic>p</italic></bold> &lt; <bold>0.001</bold></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Frequency (%) or median (range, IQR). <sup>b</sup>Mann-Whitney <italic>U</italic> test or Pearson Chi-square test. Significant <italic>p</italic>-values shown in bold. <italic>FEP</italic> First-episode psychosis, <italic>BPRS</italic> Brief Psychiatric Rating Scale, <italic>SANS</italic> Scale for the Assessment of Negative Symptoms, <italic>BPRS 10</italic> Hallucinations item, <italic>BPRS 11</italic> Unusual thought content, <italic>BPRS 12</italic> Bizarre behavior, <italic>BPRS 15</italic> Conceptual disorganization, <italic>BPRS 16</italic> Blunted affect, <italic>SANS 1</italic> Alogia, <italic>SANS 2</italic> Avolition, <italic>SANS 3 A</italic>nhedonia, <italic>GAF</italic> Global assessment of functioning.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Sample characteristics at baseline and follow-up.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Baseline</th><th>Control subjectsaN = 60</th><th>FEP patientsaN = 76</th><th>Group Differenceb</th></tr></thead><tbody><tr><td>Male</td><td>38 (63.3)</td><td>51 (67.10)</td><td>p = 0.686</td></tr><tr><td>Age</td><td>23.97 (19.10–43.87, 6.83)</td><td>23.98 (18.26–39.06, 6.55)</td><td>p = 0.420</td></tr><tr><td>Years of education</td><td>15.00 (11.00–22.00, 3.50)</td><td>12.50 (9.00–22.00, 3.88)</td><td>p = 0.004</td></tr><tr><td>BPRS 10</td><td>1 (1–1, 0.00)</td><td>2 (1–6, 4.00) (N = 75)</td><td>p &lt; 0.001</td></tr><tr><td>BPRS 11</td><td>1 (1–2, 0.00)</td><td>4 (1–7, 5.00) (N = 75)</td><td>p &lt; 0.001</td></tr><tr><td>BPRS 12</td><td>1 (1–1, 0.00)</td><td>1 (1–6, 1.00) (N = 75)</td><td>p &lt; 0.001</td></tr><tr><td>BPRS 15</td><td>1 (1–2, 0.00)</td><td>1 (1–5, 0.00) (N = 75)</td><td>p = 0.003</td></tr><tr><td>BPRS 16</td><td>1 (1–3, 0.00)</td><td>1 (1–5, 2.00) (N = 75)</td><td>p &lt; 0.001</td></tr><tr><td>SANS 1</td><td>0.00 (0.00–1.00, 0.00)</td><td>0.00 (0.00–3.00, 1.00) (N = 75)</td><td>p &lt; 0.001</td></tr><tr><td>SANS 2</td><td>0.00 (0.00–1.00, 0.00)</td><td>2.00 (0.00–5.00, 3.00) (N = 75)</td><td>p &lt; 0.001</td></tr><tr><td>SANS 3</td><td>0.00 (0.00–2.00, 0.00)</td><td>3.00 (0.00–5.00, 2.00) (N = 75)</td><td>p &lt; 0.001</td></tr><tr><td>Antipsychotic dose</td><td>0.00 (0.00–0.00, 0.00)</td><td>300.00 (0.00–1320.00, 300.00)</td><td>p &lt; 0.001</td></tr><tr><td>GAF</td><td>85.00 (55–95, 14.25)</td><td>37.50 (15–75, 8.00)</td><td>p &lt; 0.001</td></tr><tr><td rowspan="10">DSM-IV diagnosis</td><td>296.25/296.26/296.32/296.36 Major depressive disorder (n = 10)</td><td>292.12 Drug induced psychotic episode, cannabis (N = 1)</td><td rowspan="10"/></tr><tr><td>300.21 Panic disorder with agoraphobia (n = 1)</td><td>295.3 Paranoid schizophrenia (n = 12)</td></tr><tr><td>300.23 Social phobia (n = 1)</td><td>295.4 Schizophreniform disorder (n = 18)</td></tr><tr><td>300.3 Obsessive-compulsive disorder (n = 1)</td><td>295.7 Schizoaffective disorder (n = 1)</td></tr><tr><td>305 Alcohol abuse (n = 1)</td><td>295.9 Schizophrenia undefined (n = 15)</td></tr><tr><td>307.1 Anorexia Nervosa (n = 1)</td><td>296.04/296.44 Bipolar type 1 disorder (n = 7)</td></tr><tr><td rowspan="4">311 Depressive disorder NOS (n = 1)</td><td>296.24/296.34 Major depressive affective disorder with psychotic features (n = 4)</td></tr><tr><td>298.8 Brief psychotic disorder with psychotic features (n = 2)</td></tr><tr><td>298.9 Unspecified psychosis (n = 15)</td></tr><tr><td>300 OCD (n = 1)</td></tr></tbody></table></div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Follow-up</th><th>Control subjectsaN = 43</th><th>FEP patientsaN = 48</th><th>Group Differenceb</th></tr></thead><tbody><tr><td>Male</td><td>32 (74.40)</td><td>29 (60.40)</td><td>p = 0.179</td></tr><tr><td>Age</td><td>25.24 (21.07–41.50, 6.63)</td><td>25.16 (19.41–36.93, 5.70)</td><td>p = 0.382</td></tr><tr><td>BPRS 10</td><td>1 (1–2, 0.00)</td><td>2 (1–6, 0.00)</td><td>p = 0.070</td></tr><tr><td>BPRS 11</td><td>1 (1–2, 0.00)</td><td>4 (1–7, 1.00)</td><td>p &lt; 0.001</td></tr><tr><td>BPRS 12</td><td>1 (1–1, 0.00)</td><td>1 (1–4, 0.00)</td><td>p = 0.057</td></tr><tr><td>BPRS 15</td><td>1 (1–2, 0.00)</td><td>1 (1–4, 0.00)</td><td>p = 0.214</td></tr><tr><td>BPRS 16</td><td>1 (1–2, 0.00)</td><td>1 (1–4, 1.00)</td><td>p = 0.002</td></tr><tr><td>SANS 1</td><td>0.00 (0.00–0.00, 0.00)</td><td>0.00 (0.00–3.00, 0.00)</td><td>p &lt; 0.006</td></tr><tr><td>SANS 2</td><td>0.00 (0.00–2.00, 0.00)</td><td>1.00 (0.00–4.00, 2.00)</td><td>p &lt; 0.001</td></tr><tr><td>SANS 3</td><td>0.00 (0.00–2.00, 0.00)</td><td>3.00 (0.00–4.00, 3.00)</td><td>p &lt; 0.001</td></tr><tr><td>Antipsychotic dose</td><td>0.00 (0.00–60.00, 0.00)</td><td>190.00 (0.00–1050.00, 273.75)</td><td>p &lt; 0.001</td></tr><tr><td>GAF</td><td>85.00 (40–96, 11.25)</td><td>50.00 (30–90, 28.00)</td><td>p &lt; 0.001</td></tr></tbody></table></div>aFrequency (%) or median (range, IQR). bMann-Whitney U test or Pearson Chi-square test. Significant p-values shown in bold. FEP First-episode psychosis, BPRS Brief Psychiatric Rating Scale, SANS Scale for the Assessment of Negative Symptoms, BPRS 10 Hallucinations item, BPRS 11 Unusual thought content, BPRS 12 Bizarre behavior, BPRS 15 Conceptual disorganization, BPRS 16 Blunted affect, SANS 1 Alogia, SANS 2 Avolition, SANS 3 Anhedonia, GAF Global assessment of functioning.</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Summary of main functional connectivity findings by groupwise comparisons at baseline. Regional functional connectivity (FC) differences were not seen at 12 months follow-up. Clusters from the hypoconnected regions in first episode psychosis patients at baseline are shown together in Fig. 6.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab2"><label>Table 2</label><caption><p>Summary of main functional connectivity findings by groupwise comparisons at baseline. Regional functional connectivity (FC) differences were not seen at 12 months follow-up. Clusters from the hypoconnected regions in first episode psychosis patients at baseline are shown together in Fig. <xref rid="Fig6" ref-type="fig">6</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Seed</th><th>Connected region<break/>x,y,z coordinates</th><th><italic>P</italic>-value (scanner corrected)</th><th><italic>K</italic><break/>(number of voxels)</th><th>Functional connectivity (FC) at baseline</th><th>Functional connectivity<break/>associations</th></tr></thead><tbody><tr><td rowspan="6">Dorsal striatum</td><td rowspan="4">Midbrain</td><td rowspan="3">0.000003*</td><td>13</td><td rowspan="6">Decreased in patients</td><td rowspan="2">Baseline antipsychotic dose negative correlation</td></tr><tr><td rowspan="5">10</td></tr><tr><td rowspan="4">(<italic>r</italic> = −0.289, <italic>p</italic> = 0.012)</td></tr><tr><td rowspan="3">0.00006*</td></tr><tr><td>12, −15, −3</td></tr><tr><td>−12, −12, −6</td></tr><tr><td>Ventral striatum</td><td>Midbrain</td><td/><td/><td>No change</td><td>N/A</td></tr><tr><td rowspan="3">Midbrain</td><td>Cerebellum</td><td rowspan="2">0.007**</td><td rowspan="2">17</td><td rowspan="2">Decreased in patients</td><td rowspan="2">N/A</td></tr><tr><td>18, −60, −30</td></tr><tr><td>−39, −42, −45</td><td>0.007**</td><td>17</td><td/><td/></tr></tbody></table><table-wrap-foot><p><sup>*</sup>Corrected for multiple comparisons within region of interest; **Corrected for multiple comparisons within the whole brain.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Summary of main functional connectivity findings by groupwise comparisons at baseline. Regional functional connectivity (FC) differences were not seen at 12 months follow-up. Clusters from the hypoconnected regions in first episode psychosis patients at baseline are shown together in Fig. ???.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Seed</th><th>Connected regionx,y,z coordinates</th><th>P-value (scanner corrected)</th><th>K(number of voxels)</th><th>Functional connectivity (FC) at baseline</th><th>Functional connectivityassociations</th></tr></thead><tbody><tr><td rowspan="6">Dorsal striatum</td><td rowspan="4">Midbrain</td><td rowspan="3">0.000003*</td><td>13</td><td rowspan="6">Decreased in patients</td><td rowspan="2">Baseline antipsychotic dose negative correlation</td></tr><tr><td rowspan="5">10</td></tr><tr><td rowspan="4">(r = −0.289, p = 0.012)</td></tr><tr><td rowspan="3">0.00006*</td></tr><tr><td>12, −15, −3</td></tr><tr><td>−12, −12, −6</td></tr><tr><td>Ventral striatum</td><td>Midbrain</td><td/><td/><td>No change</td><td>N/A</td></tr><tr><td rowspan="3">Midbrain</td><td>Cerebellum</td><td rowspan="2">0.007**</td><td rowspan="2">17</td><td rowspan="2">Decreased in patients</td><td rowspan="2">N/A</td></tr><tr><td>18, −60, −30</td></tr><tr><td>−39, −42, −45</td><td>0.007**</td><td>17</td><td/><td/></tr></tbody></table></div>*Corrected for multiple comparisons within region of interest; **Corrected for multiple comparisons within the whole brain.</transformed-table></extracted-table></extracted-tables-set>